Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
11 Sep 2019
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.

Secukinumab safe, effective for moderate-to-severe plaque psoriasis

15 Jul 2019

Secukinumab is safe and effective for the treatment of moderate-to-severe plaque psoriasis, with effects lasting up to a year after treatment initiation, reports a recent study.

A total of 158 patients (mean age, 28±17.7 years; 57 percent male) were included in the multicentre, prospective, observational study. All patients presented with moderate-to-severe plaque psoriasis and received secukinumab. Follow-ups were conducted every 12 weeks for 52 weeks.

More than a third (34.8 percent; n=55) of the participants had psoriatic arthritis, while 41.8 percent (n=66) and 34.2 percent (n=54) were smokers and drinkers, respectively. Almost half (44.9 percent; n=71) had body mass index >30 kg/cm2 and were characterized as obese.

After 52 weeks, majority (82.9 percent; n=131) of the patients were still on secukinumab and only 27 (17.1 percent) had discontinued treatment. Reasons for discontinuation included lack of efficacy (n=8), loss of efficacy (n=15) and loss to follow-up (n=4).

At week 4, 57 percent of the participants achieved 75-percent reduction in their baseline scores in the Psoriasis Area and Severity Index (PASI). This grew to 83.5 percent and 89 percent at weeks 12 and 24, respectively, before dropping back down to 78.5 percent by week 52.

In comparison, 27.8 percent achieved a 90-percent drop in their baseline PASI scores (PASI-90) by week 4, growing to 62 percent and 64.6 percent by weeks 12 and 24. PASI-90 was at 63.2 percent at the end of the intervention period.

Only 28 participants (17.7 percent) experienced adverse events over the course of the study, the most common of which were headaches and nasopharyngitis (n=9 each; 5.7 percent). Hypertension (n=6; 3.8 percent), oral candidiasis (n=5; 3.2 percent) and diarrhoea (n=2; 1.3 percent) were other such events.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
11 Sep 2019
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.